CU20160194A7 - Composición vacunal que comprende un mutante de la interleucina-15 humana - Google Patents
Composición vacunal que comprende un mutante de la interleucina-15 humanaInfo
- Publication number
- CU20160194A7 CU20160194A7 CUP2016000194A CU20160194A CU20160194A7 CU 20160194 A7 CU20160194 A7 CU 20160194A7 CU P2016000194 A CUP2016000194 A CU P2016000194A CU 20160194 A CU20160194 A CU 20160194A CU 20160194 A7 CU20160194 A7 CU 20160194A7
- Authority
- CU
- Cuba
- Prior art keywords
- human
- mutant
- vaccine composition
- interleucine
- overexpression
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 abstract 3
- 102000003812 Interleukin-15 Human genes 0.000 abstract 3
- 108090000172 Interleukin-15 Proteins 0.000 abstract 3
- 102000056003 human IL15 Human genes 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002018 overexpression Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Composición vacunal que comprende un mutante de Ia interleucina-15 (IL-15) humana. Uso de dicho polipéptido mutante de IL-15 humana para fabricar un medicamento para Ia inmunoterapia activa de una enfermedad relacionada con Ia sobre-expresión de Ia IL-15, entre las que se encuentran algunas enfermedades autoinmunes y neoplasias hematológicas. La administración a un individuo que lo necesite de una cantidad terapéuticamente efectiva de vacuna, que comprende el polipéptido mutante de Ia IL-15 humana de Ia invención, constituye un método para Ia terapia de enfermedades relacionadas con Ia sobre-expresión de Ia IL-15.</p>
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2016000194A CU24546B1 (es) | 2016-12-30 | 2016-12-30 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
CN201780086587.4A CN110300762B (zh) | 2016-12-30 | 2017-12-20 | 包含人白介素-15的突变体的疫苗组合物 |
BR112019013542A BR112019013542A2 (pt) | 2016-12-30 | 2017-12-20 | composição de vacina, uso de um polipeptídeo, e, método para o tratamento de doenças associadas à superexpressão da il-15 |
MX2019007906A MX2019007906A (es) | 2016-12-30 | 2017-12-20 | Composicion vacunal que comprende un mutante de la interleucina-15 humana. |
RU2019122635A RU2745199C2 (ru) | 2016-12-30 | 2017-12-20 | Вакцинная композиция, содержащая мутантный человеческий интерлейкин-15 |
ES17840472T ES2892148T3 (es) | 2016-12-30 | 2017-12-20 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
PCT/CU2017/050008 WO2018121802A1 (es) | 2016-12-30 | 2017-12-20 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
US16/474,913 US20200181254A1 (en) | 2016-12-30 | 2017-12-20 | Vaccine composition comprising a mutant of human interleukin-15 |
EP17840472.9A EP3564264B1 (en) | 2016-12-30 | 2017-12-20 | Vaccine composition comprising a mutant of human interleukin-15 |
US17/531,914 US20220259300A1 (en) | 2016-12-30 | 2021-11-22 | Vaccine composition comprising a mutant of human interleukin-15 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2016000194A CU24546B1 (es) | 2016-12-30 | 2016-12-30 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20160194A7 true CU20160194A7 (es) | 2018-08-06 |
CU24546B1 CU24546B1 (es) | 2021-09-07 |
Family
ID=61188581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2016000194A CU24546B1 (es) | 2016-12-30 | 2016-12-30 | Composición vacunal que comprende un mutante de la interleucina-15 humana |
Country Status (9)
Country | Link |
---|---|
US (2) | US20200181254A1 (es) |
EP (1) | EP3564264B1 (es) |
CN (1) | CN110300762B (es) |
BR (1) | BR112019013542A2 (es) |
CU (1) | CU24546B1 (es) |
ES (1) | ES2892148T3 (es) |
MX (1) | MX2019007906A (es) |
RU (1) | RU2745199C2 (es) |
WO (1) | WO2018121802A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7547507B2 (ja) * | 2020-05-18 | 2024-09-09 | 山▲東▼先声生物制▲薬▼有限公司 | ヒトil-15変異体およびその使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
JP2001502521A (ja) | 1996-04-26 | 2001-02-27 | ベス イスラエル デアコネス メディカル センター | インターロイキン―15の拮抗剤 |
CU23093A1 (es) * | 2002-10-09 | 2005-10-19 | Ct Ingenieria Genetica Biotech | Composición vacunal que comprende interleucina-15 (il-15) |
NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
US7858081B2 (en) * | 2004-02-27 | 2010-12-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | IL-15 mutants having agonists/antagonists activity |
TW200613552A (en) * | 2004-08-11 | 2006-05-01 | Hoffmann La Roche | Mutant interleukin-15 polypeptides |
RU2007126553A (ru) * | 2004-12-13 | 2009-01-20 | Цитос Биотехнологи Аг (Ch) | Упорядоченные ряды антигенов ил-15 и их применение |
CU23716A1 (es) * | 2008-09-30 | 2011-10-05 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la actividad de la interleucina-15 |
EP3810171A4 (en) * | 2018-06-22 | 2022-04-06 | Cugene Inc. | NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOF |
-
2016
- 2016-12-30 CU CU2016000194A patent/CU24546B1/es unknown
-
2017
- 2017-12-20 ES ES17840472T patent/ES2892148T3/es active Active
- 2017-12-20 BR BR112019013542A patent/BR112019013542A2/pt unknown
- 2017-12-20 RU RU2019122635A patent/RU2745199C2/ru active
- 2017-12-20 MX MX2019007906A patent/MX2019007906A/es unknown
- 2017-12-20 US US16/474,913 patent/US20200181254A1/en not_active Abandoned
- 2017-12-20 EP EP17840472.9A patent/EP3564264B1/en active Active
- 2017-12-20 CN CN201780086587.4A patent/CN110300762B/zh active Active
- 2017-12-20 WO PCT/CU2017/050008 patent/WO2018121802A1/es unknown
-
2021
- 2021-11-22 US US17/531,914 patent/US20220259300A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CU24546B1 (es) | 2021-09-07 |
EP3564264A1 (en) | 2019-11-06 |
US20220259300A1 (en) | 2022-08-18 |
BR112019013542A2 (pt) | 2020-02-04 |
CN110300762B (zh) | 2023-05-02 |
ES2892148T3 (es) | 2022-02-02 |
CN110300762A (zh) | 2019-10-01 |
RU2019122635A3 (es) | 2021-02-01 |
RU2019122635A (ru) | 2021-02-01 |
US20200181254A1 (en) | 2020-06-11 |
RU2745199C2 (ru) | 2021-03-22 |
WO2018121802A1 (es) | 2018-07-05 |
EP3564264B1 (en) | 2021-09-08 |
MX2019007906A (es) | 2019-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181365A1 (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos | |
CO2019008932A2 (es) | Imidazo-quinolinas sustituidas como moduladores de nlrp3 | |
MX2022004374A (es) | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer. | |
DOP2015000100A (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
TR201900649T4 (tr) | Oküler hastalıkların tedavisi için mrna tedavisi. | |
MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
MX2017015105A (es) | Compuestos del peptido yy (pyy) selectivos y sus usos. | |
CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
MX2018010032A (es) | Formulaciones de antagonista de il-6 y sus usos. | |
CL2015002835A1 (es) | Nuevos derivados de piridina | |
MX2015011846A (es) | Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades. | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
CO2022003156A2 (es) | Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15rα y su uso | |
EA202091095A1 (ru) | Пероральная доставка пептидных аналогов glp-1 | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
MX2016009217A (es) | Inmunoterapia basada en liposomas. | |
CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
MX2018004296A (es) | Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada. | |
CU20160194A7 (es) | Composición vacunal que comprende un mutante de la interleucina-15 humana | |
AR115883A1 (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción | |
CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet |